| Literature DB >> 32368178 |
K Esfahani1, L Roudaia1, N Buhlaiga1, S V Del Rincon2, N Papneja1, W H Miller1.
Abstract
Compared with previous standards of care (including chemotherapy, radiotherapy, and surgery), cancer immunotherapy has brought significant improvements for patients in terms of survival and quality of life. Immunotherapy has now firmly established itself as a novel pillar of cancer care, from the metastatic stage to the adjuvant and neoadjuvant settings in numerous cancer types. In this review article, we highlight how the history of cancer immunotherapy paved the way for discoveries that are now part of the standard of care. We also highlight the current pitfalls and limitations of cancer checkpoint immunotherapy and how novel research in the fields of personalized cancer vaccines, autoimmunity, the microbiome, the tumour microenvironment, and metabolomics is aiming to solve those challenges. 2020 Multimed Inc.Entities:
Keywords: Immune checkpoint inhibitors; immune-related adverse events; metabolomics; microbiome studies; personalized cancer vaccines
Mesh:
Year: 2020 PMID: 32368178 PMCID: PMC7194005 DOI: 10.3747/co.27.5223
Source DB: PubMed Journal: Curr Oncol ISSN: 1198-0052 Impact factor: 3.677